预约演示
更新于：2025-12-16
Terbinafine Hydrochloride
盐酸特比萘芬
更新于：2025-12-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1992-12-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H26ClN |
InChIKeyBWMISRWJRUSYEX-SZKNIZGXSA-N |
CAS号78628-80-5 |
关联
85
项与 盐酸特比萘芬 相关的临床试验CTRI/2025/10/096590
A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of A Unani Formulation (Topical) Compared With Terbinafine (Topical) In The Management Of Quba (Tinea Corporis And Tinea Cruris) - NIL
ChiCTR2500113562
ED95 of Tegafur-5-Fluorouracil and Rimaclazol for respiratory depression during painless gastroscopy
NCT07152327
Effectiveness of Terbinafine Hydrochloride in the Treatment of Otomycosis: Basic and Clinical Evaluation
100 项与 盐酸特比萘芬 相关的临床结果
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的转化医学
登录后查看更多信息
100 项与 盐酸特比萘芬 相关的专利（医药）
登录后查看更多信息
1,956
项与 盐酸特比萘芬 相关的文献（医药）2025-12-31JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Hidden targets in dermatology:
In vitro
and
In silico
inhibitory effects of common 23 dermatologic drugs on human carbonic anhydrase isoenzymes I and II
Article
作者: Uslu, Harun ; Çıkrıkcı, Kübra ; Can, İlkay ; Gençer, Nahit
In this study, we have aimed to determine the in vitro and in silico effects of 23 frequently used dermatologic drugs on human carbonic anhydrase I (hCA I) and II (hCA II). The inhibitory effects of the drugs on hCA I and hCA II were determined by esterase methods. The most potent inhibitors were isotretinoin for hCA I (Ki= 5.75 µM) and valaciclovir for hCA II (Ki= 5.74 µM). Ketotifen (Ki= 6.98 µM), pantoprazole (Ki= 7.16 µM) and acyclovir (Ki= 7.31 µM) were also potent inhibitors for hCA I. Isotretinoin (Ki= 6.54 µM), brivudine (Ki= 7.44 µM) and fluconazole (Ki= 7.91 µM) were also potent inhibitors for hCA II. Terbinafine hydrochloride was a weak CA inhibitor for both of these isoenzymes (Ki= 20.58 µM for hCA I and 20.32 µM for hCA I). Therefore, the drug, having a weak CA inhibitory activity, may be preferred primarily in patients with a skin disease compared to the other drugs due to important physiological functions of CAs. Molecular docking studies have shown that acitretin and isotretinoin, in particular, will inhibit hCA I at lower concentrations and have higher docking scores. For hCA II, it was shown that Isotretinoin and Ketotifen would inhibit at lower concentrations and have higher placement scores.
2025-12-06JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test
作者: Güleli, Müge ; Torlak, Cihan ; Kurşun Baysak, Fatma ; Kızılok, Şevki ; Çalışkan, Cem ; Kartop, Remziye Azra
In this study, in-vitro release experiments were performed using a Franz Diffusion Cell system for Terbinafine Hydrochloride, which is used in the treatment of various fungal infections in the skin caused by many susceptible dermatophytes.In order to evaluate TH transdermally, it was aimed to compare the permeability between polymeric membranes synthesized with polyvinyl alc. and chitosan mixtures and com. membranes.In the transdermal drug delivery system calculations, the Fick Diffusion Law was modified and the obtained data were compared.The study was evaluated according to the USP <1724> topical drug products in semisolid form - performance tests.A new high-performance liquid chromatog. method was validated for the assay of TH released into the receptor medium in accordance with the ICH guideline.According to the results obtained during the validation process, the limit of detection value was calculated as 0.005 μg/mL and the limit of quantification value was 0.013 μg/mL.Since polymer-based synthetic membranes provide permeability according to mol. size, properties and the ideal environment for measuring and analyzing the diffusion rate of a compound, in experiments conducted using membranes of different structures, the permeability profiles of selected polymer synthetic membranes were statistically evaluated.It has been noted that the hydroxyl groups in PVA and the hydrophilic CS-g-PNDMAAm graft copolymer act at varying rates to enhance or reduce the permeability across the membrane by promoting its diffusion.NaY zeolite has been shown to function as an adsorbent against the medication, lessening the impact of hydrophilic PVA without supplying permeability.
2025-11-02Expert Opinion On Drug Safety
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Article
作者: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Dai, Liyang ; Liu, Songqing ; Wu, Fan ; Zhang, Tongyan
BACKGROUND:
The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.
RESEARCH DESIGN AND METHODS:
We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.
RESULTS:
A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.
CONCLUSIONS:
Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.
100 项与 盐酸特比萘芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲癣 | 澳大利亚 | 2003-12-22 | |
| 体癣 | 澳大利亚 | 2003-12-22 | |
| 股癣 | 澳大利亚 | 2003-12-22 | |
| 足癣 | 美国 | 1999-03-09 | |
| 皮肤真菌病 | 中国 | 1997-01-01 | |
| 皮肤念珠菌病 | 日本 | 1993-07-02 | |
| 真菌病 | 日本 | 1993-07-02 | |
| 癣 | 日本 | 1993-07-02 | |
| 花斑癣 | 日本 | 1993-07-02 | |
| 头癣 | 美国 | 1992-12-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 红斑 | 临床1期 | 美国 | 2017-10-15 | |
| 粘膜念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| 口腔念珠菌病 | 临床阶段不明 | 美国 | 2001-08-31 | |
| HIV感染 | 临床阶段不明 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 384 | 壓蓋憲獵窪壓窪壓醖鏇(鹹齋簾觸憲餘獵鑰鏇網) = 網鑰齋夢衊窪繭餘觸遞 衊獵積鹽繭範鏇廠壓簾 (糧襯範鏇餘觸醖簾窪鬱 ) 更多 | 不佳 | 2025-01-10 | |||
临床1期 | 20 | 網範淵鑰窪鏇構簾簾觸(窪顧淵鏇獵壓獵憲餘壓) = Adverse events (five patients), such as headache (n = 3), seasonal allergy (n = 1), and neck pain (n = 1), were considered unrelated to MOB015B; no application site reactions or study discontinuations due to an adverse event were observed. 築齋鬱鏇壓艱襯簾鬱積 (獵鏇鬱膚壓壓餘鬱鬱繭 ) | 积极 | 2024-08-19 | |||
临床3期 | - | 窪壓夢憲範齋餘願構醖(艱齋範壓鬱夢鹹餘範遞) = 選鹹醖窪衊憲鏇構築糧 積簾襯醖製淵繭觸鏇鹹 (遞窪遞膚顧網製遞襯網 ) 更多 | 非优 | 2021-07-01 | |||
vehicle | 窪壓夢憲範齋餘願構醖(艱齋範壓鬱夢鹹餘範遞) = 選壓鹹鹽構顧願餘積夢 積簾襯醖製淵繭觸鏇鹹 (遞窪遞膚顧網製遞襯網 ) 更多 | ||||||
临床3期 | 452 | 鑰獵顧鬱夢簾廠觸餘鬱(壓鹽範製鹽顧餘觸鹽顧) = 構顧鑰築願範憲鬱製積 淵餘製蓋壓淵壓夢衊餘 (壓顧醖淵衊糧鬱壓構憲 ) 更多 | 非劣 | 2020-06-25 | |||
鑰獵顧鬱夢簾廠觸餘鬱(壓鹽範製鹽顧餘觸鹽顧) = 構廠顧壓蓋網壓選築窪 淵餘製蓋壓淵壓夢衊餘 (壓顧醖淵衊糧鬱壓構憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用